Merger Notification - Announcement according to § 10 Cartel Act
Cheplapharm Arzneimittel GmbH; Eli Lilly and Company
BWB/Z-6273
On 12.05.2023 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Cheplapharm Arzneimittel GmbH (Greifswald / Germany) intends to acquire from Eli Lilly and Company (Indianapolis / United States of America), and Eli Lilly Kinsale Limited (Dunderrow / Ireland), the pharmaceutical product Zyprexa, which is indicated for the treatment of schizophrenia and bipolar disorder, and all assets associated with such product on a world-wide basis (excluding South Korea). The proposed concentration
concerns pharmaceutical products.
Affected industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations.
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 09.06.2023.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 10.06.2023 .